Your browser doesn't support javascript.
loading
Initial local excision for clinical T1 rectal cancer showed comparable overall survival despite high local recurrence rate: a propensity-matched analysis.
Hyun, Jong Hee; Alhanafy, Mohamed K; Park, Hyoung-Chul; Park, Su Min; Park, Sung-Chan; Sohn, Dae Kyung; Kim, Duck-Woo; Kang, Sung-Bum; Jeong, Seung-Yong; Park, Kyu Joo; Oh, Jae Hwan.
Afiliação
  • Hyun JH; Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Alhanafy MK; Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Park HC; Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Park SM; Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Park SC; Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Sohn DK; Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Kim DW; Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Kang SB; Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Jeong SY; Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • Park KJ; Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • Oh JH; Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Ann Coloproctol ; 38(2): 166-175, 2022 Apr.
Article em En | MEDLINE | ID: mdl-34610653
ABSTRACT

PURPOSE:

Local excision (LE) is an alternative initial treatment for clinical T1 rectal cancer, and has avoided potential morbidity. This study aimed to evaluate the clinical outcomes of LE compared with total mesorectal excision (TME) for clinical T1 rectal cancer.

METHODS:

Between January 2000 and December 2011, we retrospectively reviewed from multicenter data in patients with clinically suspected T1 rectal cancer treated with either LE or TME. Of 1,071 patients, 106 were treated with LE and 965 were treated with TME. The data were analyzed using propensity score matching, with each group comprising 91 patients.

RESULTS:

After propensity score matching, the median follow-up time was 60.8 months (range, 0.6-150.6 months). After adjustment for the necessary variables, patients who underwent LE showed a significantly higher local recurrence rate than did those who underwent TME; however, there were no differences in disease-free survival and overall survival. In the multivariate analysis, age (hazard ratio [HR], 9.620; 95% confidence interval [CI], 3.415-27.098; P<0.001) and angiolymphatic invasion (HR, 3.63; 95% confidence interval, 1.33-9.89; P=0.012) were independently associated with overall survival. However, LE was neither associated with overall survival nor disease-free survival.

CONCLUSION:

LE for clinical T1 rectal cancer yielded a higher local recurrence rate than did TME. Nevertheless, LE provided comparable overall survival rate and can be proposed as an optional treatment in terms of organ-preserving strategies.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Ann Coloproctol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Ann Coloproctol Ano de publicação: 2022 Tipo de documento: Article